Impressum - Zedira GmbH

News

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie

Co-authored posters at ICDS 2022

Successful ISO9001:2015 recertification

Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)

Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie

Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

All news

Blog

Transglutaminase antibodies and neurological manifestations of gluten sensitivity

DZG Aktuell: Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227

Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible?

Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Tridegin as FXIIIa inhibitor

Microbial transglutaminase: from discovery to market

Tissue transglutaminase inhibitors

Tissue transglutaminase in Alzheimers Disease

Factor XIIIa: novel target for anticoagulation?

Microbial transglutaminase for site-specific protein conjugation

Transglutaminases: current research and applications - future directions

All posts

Events

There are no events.

All events

Phone:		+49 6151 66628-0
Fax:		+49 6151 66628-19
E-mail:		contact@zedira.com

Handelsregister:		Amtsgericht Darmstadt HRB 86081
Umsatzsteuer Identifikationsnummer:		DE255202462

Geschäftsführer:		Dr. Martin Hils Dr. Ralf Pasternack